

AGENCY OFFERING AGREEMENT (CPC/IPO/SHARES)

THIS AGREEMENT dated for reference January 28, 2008 is made

BETWEEN

AURICLE BIOMEDICAL CORPORATION, 208-5455 West
Boulevard, Vancouver, British Columbia, V6M 3WS

(the “Issuer”);

AND

CANACCORD CAPITAL CORPORATION, 2200-609
Granville Street, Vancouver, British Columbia, V7Y 1H2

(the “Agent”).

WHEREAS:

A. The Issuer wishes to raise money in accordance with the CPC Policy and for the purposes set forth in its Prospectus, which is to be filed by the Issuer with the Commissions and the Exchange, by offering for sale certain of its shares;

B. The Issuer wishes to appoint the Agent to distribute those shares and the Agent is willing to accept the appointment on the terms and conditions of this Agreement;

THE PARTIES to this Agreement therefore agree:

1. DEFINITIONS

In this Agreement:

- (a) “Administration Fee” means the fee to be paid to the Agent by the issuer in consideration of the Agent’s services in connection with the coordination and review of the Prospectus;
- (b) “Agent’s Commission” has the meaning given to it in Section 7.1;
- (c) “Agent’s Fee” means the fee which is set out in this Agreement and which is payable by the Issuer to the Agent in consideration of the services performed by the Agent under this Agreement;
- (d) “Agent’s Warrants” means the share purchase warrants of the Issuer which will be issued as part of the Agent’s Fee and which have the terms provided in this Agreement and the certificates representing such share purchase warrants;
- (e) “Agent’s Warrant Shares” means any common shares in the capital of the Issuer that may be issued on exercise of the Agent’s Warrants;

- (f) “Agreement in Principle” has the meaning defined in the CPC Policy;
- (g) “Applicable Legislation” means the securities acts in the Selling Provinces, the regulations and rules made thereunder, all administrative policy statements, instruments, blanket orders, notices, directions and rulings issued by the Commissions and the rules and policies of the Exchange, in particular, the CPC Policy;
- (h) “Approval Date” means the date the Shares commence trading on the Exchange;
- (i) “Certificates” means the certificates representing the Shares and Agent’s Warrants;
- (j) “Closing” means the closing of the purchase and sale, and the issuance by the Issuer, of the Shares;
- (k) “Closing Day” means such day following the Offering Day as may be agreed to by the Issuer and the Agent on which the Closing takes place;
- (l) “Commissions” means the securities commissions in the Selling Provinces;
- (m) “CPC Policy” means policy 2.4 of the Exchange entitled, “Capital Pool Companies” as may be amended by the Exchange from time to time;
- (n) “Distribution” means the distribution or sale of the Securities pursuant to this Agreement;
- (o) “Effective Date” means the date on which an MRRS decision document for the final Prospectus is issued by the Principal Regulator;
- (p) “Exchange” means the TSX Venture Exchange Inc.;
- (q) “Material Change” has the meaning defined in the Applicable Legislation;
- (r) “Material Fact” has the meaning defined in the Applicable Legislation;
- (s) “Misrepresentation” has the meaning defined in the Applicable Legislation;
- (t) “MRRS” means the Mutual Reliance Review System for Prospectuses and Annual Information Forms under National Policy 43-201;
- (u) “Offering” means the offering of the Shares under the Prospectus;
- (v) “Offering Day” means the day chosen by the Agent to contract the purchases of Shares by the purchasers;
- (w) “Offering Price” means \$0.10 per Share;
- (x) “Principal Regulator” means the British Columbia Securities Commission;

- (y) “Proceeds” means the gross proceeds of the Offering, less:
 - (i) the Agent’s Commission;
 - (ii) the Administration Fee;
 - (iii) the expenses of the Agent in connection with the Offering which have not been repaid by the Issuer; and
 - (iv) any amount already received by the Issuer.
- (z) “Prospectus” means the preliminary prospectus and the final prospectus filed or intended to be filed by the Issuer with the Regulatory Authorities in connection with the Offering and any amendments to the preliminary prospectus and final prospectus which may be filed with the Regulatory Authorities;
- (aa) “Qualifying Transaction” has the meaning defined in the CPC Policy;
- (bb) “Regulatory Authorities” means the Commissions and the Exchange;
- (cc) “Securities” means the Shares, Agent’s Warrants, Agent’s Warrant Shares and any common shares of the Issuer which may be offered for sale under the Prospectus, pursuant to a secondary or shareholder offering;
- (dd) “Selling Provinces” means British Columbia and Alberta or in such other provinces as may be agreed to by the Issuer and the Agent;
- (ee) “Shares” means the 2,000,000 previously unissued common shares of the Issuer to be offered by the Issuer pursuant to this Agreement having the terms provided in this Agreement; and
- (ff) “Significant Assets” has the meaning defined in the CPC Policy.

2. APPOINTMENT OF AGENT

The Issuer appoints the Agent as its exclusive agent and the Agent accepts the appointment and will act as the exclusive agent of the Issuer to offer the Shares for sale under the Prospectus at the Offering Price on a commercially reasonable efforts basis.

3. THE SHARES

Upon receipt in full of the cash consideration in respect of the Offering Price for the Shares, such Shares will be issued and registered in the names and denominations as instructed by the Agent on the Closing Day.

4. FILING OF PROSPECTUS

4.1 The Issuer will cause the Prospectus to be filed with the Regulatory Authorities, will deliver all necessary copies of the Prospectus to the Regulatory Authorities and will use its best efforts to have the Prospectus accepted by the Regulatory Authorities.

4.2 The Issuer will provide the Agent with as many copies of the Prospectus as the Agent reasonably requests.

4.3 Delivery of the Prospectus and any amendment thereto shall constitute a representation and warranty by the Issuer to the Agent that all information and statements (except information and statements relating solely to the Agent) contained in the Prospectus and any amendment thereto are true and correct in all material respects at the time of delivery thereof and contain no Misrepresentations and constitute full, true and plain disclosure of all Material Facts relating to the Issuer and the Securities and that no Material Fact or material information has been omitted therefrom (except facts of information relating solely to the Agent) which is required to be stated therein or is necessary to make statements of information contained therein not misleading in light of the circumstances under which they were made. Such delivery shall also constitute the Issuer's consent to the Agent's use of the Prospectus, any amendment thereto and any other documents supplied to the Agent by the Issuer for the purpose of the sale of Shares in compliance herewith and with the Applicable Legislation.

5. LISTING APPLICATION AND CONDUCT OF THE OFFERING

5.1 Prior to the Closing Day, the Issuer will make application to list the Shares and Agent's Warrant Shares on the Exchange and conditional approval of such application must be obtained from the Exchange prior to Closing.

5.2 Following the Effective Date and after consulting with the Exchange, the Issuer and the Agent will set the Offering Day.

5.3 The Offering Day will be on or before the earlier of the day which is:

- (a) 90 days after the Effective Date; and
- (b) 12 months after the date of the issue by the Principal Regulator of the MRRS decision document for the preliminary Prospectus.

5.4 Immediately after the Offering Day, the Issuer shall take all necessary steps to complete and file with the Exchange its application for listing with all other documentation required by the Exchange, to allow for the listing and posting for trading of the common shares of the Issuer on the Exchange, which is to occur no earlier than 10 days after the Offering Day and no later than 2 days after the Closing Day unless otherwise agreed to by the Agent.

5.5 The Agent will advise the Issuer and its counsel in writing when the Distribution under the Prospectus is complete.

6. OPINIONS AND CERTIFICATES

6.1 On the Closing Day, the Issuer will deliver the following documents to the Agent and its counsel in a form acceptable to them:

- (a) evidence of the necessary approval of the Regulatory Authorities for the Offering;
- (b) an opinion of counsel for the Issuer, dated as of the Closing Day and addressed to the Agent and its counsel, in form and substance satisfactory to the Agent, acting reasonably, in respect of those matters set forth in Schedule “A” hereto, subject to the usual and customary assumptions, limitations and qualifications;
- (c) a certificate of the Issuer, dated as of the Closing Day and signed by the chief executive officer and chief financial officer of the Issuer or such other officers approved by the Agent, certifying certain facts relating to the Issuer and its affairs (the “Officers’ Certificate”); and
- (d) any other certificates, comfort letters or opinions in connection with any matter related to the Prospectus which are reasonably requested by the Agent or its counsel.

7. AGENT’S FEE

7.1 In consideration of the services performed by the Agent under this Agreement, the Issuer agrees to pay the Agent, at Closing, a commission of 10% of the Offering Price per Share sold, whether purchased by the Agent for its own account or for its clients or purchased by other members of the Exchange for their own accounts or for their clients (the “Agent’s Commission”).

7.2 In consideration for acting as Agent, the Issuer will issue, at Closing, Agent’s Warrants to the Agent or to members of its selling group as directed by the Agent entitling the Agent to purchase that number of Agent’s Warrant Shares equal to up to 10% of the Shares sold under the Offering to a maximum of up to 200,000 Agent’s Warrant Shares. The Agent’s Warrants will be non-transferable and one Agent’s Warrant will entitle the holder to purchase one common share of the Issuer. The right to purchase Agent’s Warrant Shares under the Agent’s Warrants may be exercised at any time up to the close of business 24 months from the Approval Date at the Offering Price, provided that no more than 50% of the aggregate number of Agent’s Warrant Shares which may be acquired by the Agent on exercise of the Agent’s Warrants will be sold by the Agent prior to completion of the Qualifying Transaction. The terms governing the Agent’s Warrants will include, among other things, provisions for the appropriate adjustment in the class, number and price of the Agent’s Warrant Shares upon the occurrence of certain events, including any subdivision, consolidation or reclassification of the Issuer’s common shares, the payment of stock dividends or the amalgamation of the Issuer. The issue of the Agent’s Warrants will not restrict or prevent the Issuer from obtaining any other financing, nor from issuing additional securities or rights during the period within which the Agent’s Warrants are exercisable.

7.3 In consideration of the Agent’s services in connection with the coordination and review of the Offering and the Prospectus, the Issuer will pay the Agent, on completion or cancellation

of the Offering, the Administration Fee of \$10,000. The Issuer's obligation to pay the Administration Fee shall survive the termination of this agreement.

8. CLOSING

8.1 On Closing, the Issuer will deliver the Certificates to the Agent against payment of the Proceeds.

8.2 If the Issuer has satisfied all of its obligations under this Agreement, on Closing, the Agent will pay the Proceeds to the Issuer against delivery of the Certificates.

8.3 The obligation of the Agent to pay the Proceeds to the Issuer shall be subject to the following conditions precedent:

- (a) completion by the Agent of due diligence on the Issuer to its reasonable satisfaction;
- (b) the Issuer shall have performed or complied with each covenant and obligation herein provided on its part to be performed or complied with;
- (c) each of the representations and warranties of the Issuer herein shall continue to be true, and the Officer's Certificate shall contain certification to that effect; and
- (d) the Issuer shall have, to the satisfaction of the Agent's counsel, taken or caused to be taken all steps and proceedings which may be requisite under the Applicable Legislation to qualify the Distribution of the Shares to the public in the Selling Provinces through registrants who have complied with the provision of the Applicable Legislation, including the filing and the obtaining of MRRS decision documents for the preliminary and final Prospectus.

9. COVENANTS AND OBLIGATIONS OF THE ISSUER

9.1 The Issuer covenants and agrees that it has complied with and will abide by and comply with all Applicable Legislation and will complete all filings required of the Issuer under the Applicable Legislation and by the Exchange in connection with the Offering, the Prospectus and the listing of the Shares and Agent's Warrant Shares.

9.2 The Issuer covenants and agrees that:

- (a) it has not and will not carry on any business other than the identification and evaluation of assets or businesses in connection with a potential Qualifying Transaction, until completion of a Qualifying Transaction; and
- (b) it has not entered into an Agreement in Principle.

9.3 If, after the Prospectus is filed with the Regulatory Authorities but before the conclusion of the Distribution, a Material Change or change in a Material Fact occurs in the affairs of the Issuer, the Issuer will:

- (a) notify the Agent immediately, in writing, with full particulars of the change;
- (b) file with the Regulatory Authorities as soon as practicable, and in any event no later than 10 days after the change occurs, an amendment to the Prospectus in a form acceptable to the Agent disclosing the Material Change; and
- (c) provide as many copies of that amendment to the Agent as the Agent may reasonably request.

9.4 The Issuer shall in good faith discuss with the Agent any fact or change in circumstances (actual and anticipated, contemplated or threatened, whether financial or otherwise) which is of such a nature that there is reasonable doubt as to whether notice in writing need be given to the Agent pursuant to the previous Subsection.

9.5 Until the Qualifying Transaction has occurred, the Issuer shall:

- (a) notify the Agent of any change proposed to be made in the corporate undertaking of the Issuer;
- (b) notify the Agent of any proposed issuance of a control block of securities (meaning a holding of Shares or other securities of the Issuer or both held by a person or combination of persons acting jointly or in concert to which are attached more than 20% of the voting rights attached to all outstanding securities of the Issuer carrying voting rights);
- (c) notify the Agent of any Agreement in Principle being reached with respect to a Qualifying Transaction;
- (d) notify the Agent of any proposed change to the constitution of the board of directors of the Issuer, or to the membership of senior management of the Issuer, including any resignations, terminations or departures of members of the Board of Directors or senior management;
- (e) provide the Agent with copies of all financial statements, press releases, promotional materials, material change reports, materials prepared in connection with the Issuer's annual general meeting and any special meetings of shareholders, annual reports, and financial statements prepared by or for the Issuer forthwith upon preparation or receipt of the same; and
- (f) notify the Agent of any circumstances where the Issuer does not expect to comply with a filing deadline imposed by regulatory authorities, such notification to be provided at least 10 business days before the deadline;

forthwith upon the proposal of such change, issuance, sale, disposition or agreement.

10. TERMINATION

10.1 The Agent may terminate its obligations under this Agreement by notice in writing to the Issuer at any time before the Closing if:

- (a) there is an event, accident, governmental law or regulation or other occurrence of any nature which, in the opinion of the Agent, seriously affects or will seriously affect the financial markets or the business of the Issuer or the ability of the Agent to perform its obligations under this Agreement or an investor's decision to purchase Shares;
- (b) an adverse Material Change or change in a Material Fact relating to any of the Securities occurs or is announced by the Issuer;
- (c) following a consideration of the history, business, products, property or affairs of the Issuer or its principals and promoters, or the state of the financial markets in general, or the state of the market for the Issuer's securities in particular, or the possibility of investors exercising their statutory rights to withdraw from a purchase of the Issuer's securities, the Agent determines, in its sole discretion, that it is not in the interest of investors to complete the Offering;
- (d) the Securities cannot, in the opinion of the Agent, be marketed due to the state of the financial markets, or the market for the Shares in particular; or
- (e) an enquiry or investigation (whether formal or informal) in relation to the Issuer, or the Issuer's directors, officers or promoters, is commenced or threatened by an officer or official of any competent authority.

10.2 The Agent may terminate its obligations under this Agreement at any time if:

- (a) any order to cease trading (including communicating with persons in order to obtain expressions of interest) in the securities of the Issuer is made by a competent regulatory authority and that order is still in effect;
- (b) the Issuer is in breach of any material term of this Agreement; or
- (c) the Agent determines that any of the representations or warranties made by the Issuer in this Agreement is false or has become false.

10.3 If the Agent exercises its right to terminate this Agreement, then the Issuer will immediately issue a press release setting out particulars of the termination.

10.4 The Agent, at its sole discretion, may terminate this Agreement in writing if an MRRS decision document for the final Prospectus is not issued by the Principal Regulator within 120 days of the reference date of this Agreement.

11. WARRANTIES AND REPRESENTATIONS

11.1 The Issuer warrants and represents to the Agent that:

- (a) the Issuer is a valid and subsisting corporation duly incorporated and in good standing under the laws of the jurisdiction in which it is incorporated, continued or amalgamated;

- (b) the Issuer is duly registered and licenced to carry on business in the jurisdictions in which it carries on business or owns property where so required by the laws of that jurisdiction and is not otherwise precluded from carrying on business or owning property in such jurisdictions by any other commitment, agreement or document;
- (c) the Issuer has full corporate power and authority to carry on its business as now carried on by it and to undertake the Offering and this Agreement has been, or will be by the Closing, duly authorized by all necessary corporate action on the part of the Issuer;
- (d) the Issuer has not carried on any business other than the identification and evaluation of assets or business in connection with a potential Qualifying Transaction, and will continue to limit its business in this manner until the completion of the Qualifying Transaction;
- (e) the Issuer has not entered into an Agreement in Principle and has no predetermined plans respecting an acquisition of Significant Assets;
- (f) all of the material transactions of the Issuer have been promptly and properly recorded or filed in its books or records and its minute books or records contain all records of the meetings and proceedings of its directors, shareholders, and other committees, if any, since inception;
- (g) the authorized capital of the Issuer is as disclosed in the Prospectus and the issued and outstanding common shares of the Issuer are fully paid and non-assessable and, except as disclosed in the Prospectus, no person has any right, agreement or option, present or future, contingent or absolute, or any right capable of becoming such a right, agreement or option, for the issue or allotment of any unissued shares in the capital of the Issuer or any other security convertible into or exchangeable for any such shares, or to require the Issuer to purchase, redeem or otherwise acquire any of the issued and outstanding shares in its capital;
- (h) the Issuer has no subsidiaries;
- (i) the Issuer will reserve or set aside sufficient common shares in its treasury to issue the Shares and Agent's Warrant Shares;
- (j) the Prospectus will contain full, true and plain disclosure of all Material Facts in relation to the Issuer, its business and its securities, will contain no Misrepresentations, will be accurate in all material respects and will omit no fact, the omission of which will make such representations misleading or incorrect;
- (k) the financial statements of the Issuer which form part of the Prospectus have been prepared in accordance with Canadian generally accepted accounting principles, present fairly, in all material respects, the financial position and all material liabilities (accrued, absolute, contingent or otherwise) of the Issuer as at the date of the financial statements and there have been no adverse material changes in the financial position of the Issuer since the date thereof, and the business of the

Issuer has been carried on in the usual and ordinary course consistent with past practice except as fully and plainly disclosed in the Prospectus;

- (l) the auditors of the Issuer who audited the financial statements of the Issuer for the most recent financial year-end and who provided their audit report thereon are independent public accountants as required under Applicable Legislation and there has never been a reportable disagreement (within the meaning of National Instrument 51-102) with the present auditors of the Issuer;
- (m) the Issuer has complied and will comply fully with the requirements of all applicable corporate and securities laws and administrative policies and directions, including, without limitation, Applicable Legislation and its regulations and the *Business Corporations Act* (British Columbia) in relation to the issue and trading of its securities and in all matters relating to the Offering;
- (n) the Issuer is in compliance with all applicable laws, regulations and statutes in the jurisdictions in which it carries on business;
- (o) the issue and sale of the Securities by the Issuer does not and will not conflict with, and does not and will not result in a breach of, or constitute a default under (A) any statute, rule or regulation applicable to the Issuer including, without limitation, the Applicable Legislation; (B) the constating documents, by-laws or resolutions of the Issuer which are in effect at the date hereof; (C) any agreement, debt instrument, mortgage, note, indenture, instrument, lease or other document to which the Issuer is a party or by which it is bound; or (D) any judgment, decree or order binding the Issuer or the property or assets of the Issuer;
- (p) the Issuer is not a party to any actions, suits or proceedings which could materially affect its business or financial condition, and no such actions, suits or proceedings are contemplated or have been threatened;
- (q) there are no judgments against the Issuer which are unsatisfied, nor are there any consent decrees or injunctions to which the Issuer is subject;
- (r) there is not presently, and will not be until the conclusion of the Distribution, any Material Change or change in any Material Fact relating to the Issuer which has not been or will not be fully disclosed in the Prospectus;
- (s) no order ceasing, halting or suspending trading in securities of the Issuer nor prohibiting the sale of such securities has been issued to and is outstanding against the Issuer or its directors, officers or promoters or against any other companies that have common directors, officers or promoters and no investigations or proceedings for such purposes are pending or threatened;
- (t) the Issuer has filed all federal, provincial, local and foreign tax returns which are required to be filed, or has requested extensions thereof, and has paid all taxes required to be paid by it and any other assessment, fine or penalty levied against it, or any amounts due and payable to any governmental authority, to the extent that any of the foregoing is due and payable;

- (u) the Issuer has established on its books and records reserves which are adequate for the payment of all taxes not yet due and payable and there are no liens for taxes on the assets of the Issuer except for taxes not yet due, and there are no audits of any of the tax returns of the Issuer which are known by the Issuer's management to be pending, and there are no claims which have been or may be asserted relating to any such tax returns which, if determined adversely, would result in the assertion by any governmental agency of any deficiency which would have a material adverse effect on the properties, business or assets of the Issuer;
- (v) the Issuer does not have any loans or other indebtedness outstanding which has been made to any of its shareholders, officers, directors or employees, past or present, or any person not dealing at "arm's length" (as such term is used in the *Income Tax Act* (Canada));
- (w) other than the Agent, no person, firm or corporation acting or purporting to act at the request of the Issuer is entitled to any brokerage, agency or finder's fee in connection with the transactions described herein; and
- (x) the warranties and representations in this Subsection are true and correct and will remain so as of the conclusion of the distribution under the Prospectus.

11.2 The Agent warrants and represents to the Issuer that:

- (a) it is a valid and subsisting corporation under the law of the jurisdiction in which it was incorporated, continued or amalgamated;
- (b) it is a member in good standing of the Exchange;
- (c) it is appropriately registered under the Applicable Legislation so as to permit it to lawfully fulfill its obligations hereunder; and
- (d) it has complied with and will fully comply with the requirements of all Applicable Legislation, its rules and regulations and the by-laws and rules of the Exchange, in relation to trading in the Securities and all matters relating to the Offering.

12. EXPENSES OF AGENT

12.1 The Issuer will pay all of the expenses of the Offering and all the expenses reasonably incurred by the Agent in connection with the Offering including, without limitation, the fees and expenses of the solicitors for the Agent.

12.2 The Issuer will pay the expenses referred to in the previous Subsection even if the Prospectus and this Agreement are not accepted by the Regulatory Authorities or the transactions contemplated by this Agreement are not completed or this Agreement is terminated, unless the failure of acceptance or completion or the termination is the result of a breach of this Agreement by the Agent.

12.3 The Agent may, from time to time, render accounts to the Issuer for its expenses for payment on the dates set out in the accounts.

12.4 Upon direction from the Issuer, the Agent may deduct its reasonable expenses in connection with the Offering from the proceeds of the Offering, including expenses for which an account has not yet been rendered to the Issuer.

13. INDEMNITY

13.1 The Issuer (the “Indemnitor”) hereby agrees to indemnify and hold the Agent, and its affiliates, and each of their directors, officers, employees and agents (hereinafter referred to as the “Personnel”) harmless from and against any and all expenses, losses (other than loss of profits), fees, claims, actions (including shareholder actions, derivative actions or otherwise), damages, obligations, or liabilities, whether joint or several, and the reasonable fees and expenses of their counsel, that may be incurred in advising with respect to and/or defending any actual or threatened claims, actions, suits, investigations or proceedings to which the Agent and/or its Personnel may become subject or otherwise involved in any capacity under any statute or common law, or otherwise insofar as such expenses, losses, claims, damages, liabilities or actions arise out of or are based, directly or indirectly, upon the performance of professional services rendered to the Indemnitor by the Agent and its Personnel hereunder, or otherwise in connection with the matters referred to in this Agreement (including the aggregate amount paid in reasonable settlement of any such actions, suits, investigations, proceedings or claims that may be made against the Agent and/or its Personnel, provided that the Indemnitor has agreed to such settlement), provided, however, that this indemnity shall not apply to the extent that a court of competent jurisdiction in a final judgment that has become non-appealable shall determine that:

- (a) the Agent and/or its Personnel have been negligent or have committed wilful misconduct or any fraudulent act in the course of such performance; and
- (b) the expenses, losses, claims, damages or liabilities, as to which indemnification is claimed, were directly caused by the negligence, wilful misconduct or fraud referred to in 13.1(a).

13.2 Without limiting the generality of the foregoing, this indemnity shall apply to all expenses (including legal expenses), losses, claims and liabilities that the Agent may incur as a result of any action or litigation that may be threatened or brought against the Agent.

13.3 If for any reason (other than the occurrence of any of the events itemized in 13.1(a) and 13.1(b) above), the foregoing indemnification is unavailable to the Agent or any Personnel or insufficient to hold the Agent or any Personnel harmless, then the Indemnitor shall contribute to the amount paid or payable by the Agent or any Personnel as a result of such expense, loss, claim, damage or liability in such proportion as is appropriate to reflect not only the relative benefits received by the Indemnitor on the one hand and the Agent or any Personnel on the other hand but also the relative fault of the Indemnitor and the Agent or any Personnel, as well as any relevant equitable considerations; provided that the Indemnitor shall in any event contribute to the amount paid or payable by the Agent or any Personnel as a result of such expense, loss, claim, damage or liability and any excess of such amount over the amount of the fees received by the Agent hereunder.

13.4 The Indemnitor agrees that in case any legal proceeding shall be brought against the Indemnitor and/or the Agent by any governmental commission or regulatory authority or any

stock exchange or other entity having regulatory authority, either domestic or foreign, or shall investigate the Indemnitor and/or the Agent, and/or any Personnel of the Agent shall be required to testify in connection therewith or shall be required to respond to procedures designed to discover information regarding, in connection with, or by reason of the performance of professional services rendered to the Indemnitor by the Agent, the Agent shall have the right to employ its own counsel in connection therewith provided the Agent acts reasonably in selecting such counsel, and the reasonable fees and expenses of such counsel as well as the reasonable costs (including an amount to reimburse the Agent for time spent by the Agent's Personnel in connection therewith) and out-of-pocket expenses incurred by their Personnel in connection therewith shall be paid by the Indemnitor as they occur.

13.5 Promptly after receipt of notice of the commencement of any legal proceeding against the Agent or any of the Agent's Personnel or after receipt of notice of the commencement or any investigation, which is based, directly or indirectly, upon any matter in respect of which indemnification may be sought from the Indemnitor, the Agent will notify the Indemnitor in writing of the commencement thereof and, throughout the course thereof, will provide copies of all relevant documentation to the Indemnitor, will keep the Indemnitor advised of the progress thereof and will discuss with the Indemnitor all significant actions proposed. However, the failure by the Agent to notify the Indemnitor will not relieve the Indemnitor of its obligations to indemnify the Agent and/or any Personnel. The Indemnitor shall, on behalf of itself and the Agent and/or any Personnel, as applicable, be entitled to (but not required) to assume the defence of any suit brought to enforce such legal proceeding; provided, however, that the defence shall be conducted through legal counsel acceptable to the Agent and/or any Personnel, as applicable, acting reasonably, that no settlement of any such legal proceeding may be made by the Indemnitor without the prior written consent of the Agent and/or any Personnel, as applicable, and none of the Agent and/or any Personnel, as applicable, shall be liable for any settlement of any such legal proceeding unless it has consented in writing to such settlement, such consent not to be unreasonably withheld. The Agent and its Personnel shall have the right to appoint its or their own separate counsel at the Indemnitor's cost provided the Agent acts reasonably in selecting such counsel.

13.6 The indemnity and contribution obligations of the Indemnitor shall be in addition to any liability which the Indemnitor may otherwise have, shall extend upon the same terms and conditions to the Personnel of the Agent and shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of the Indemnitor, the Agent and any of the Personnel of the Agent. The foregoing provisions shall survive the completion of professional services rendered under this Agreement or any termination of this Agreement.

14. RIGHT OF FIRST REFUSAL

14.1 The Issuer will notify the Agent (the "Financing Notice") of the terms of any further brokered equity financing (or securities convertible into equity) that it requires or proposes to obtain during the term of this Agreement and until that day (the "ROFR Termination Date") which is the earlier of:

- (a) that day which falls 24 months from the Approval Date; and

- (b) the date of the initial submission by the Issuer to the Exchange with respect to the Qualifying Transaction;

and the Agent will have the right of first refusal to provide any such financing on the same terms or on terms no less favourable as the terms set out in the Financing Notice proposed during that period.

14.2 The Issuer will notify the Agent (the “Q.T. Notice”) of any Agreement in Principle which is reached with respect to a Qualifying Transaction during the term of this Agreement and before the ROFR Termination Date, and the Agent will have the right of first refusal to act as the Issuer’s sponsor with respect to the Qualifying Transaction if a sponsor is required by the Exchange.

14.3 In addition to the Q.T. Notice, the Issuer will provide the Agent with:

- (a) copies of the most recent audited financial statements and unaudited financial statements of the Issuer and appropriate financial information for any Significant Assets the Issuer proposes to purchase in the Qualifying Transaction (the “Target”), prepared as of a date satisfactory to the Agent;
- (b) a copy of the Target’s business plan or technical report, as the case may be; and
- (c) copies of all such other information concerning the business of the Target as the Agent may request;

(collectively, the “Q.T. Reports”) in order that the Agent may undertake an investigation of the business of the Target.

14.4 The right of first refusal must be exercised by the Agent:

- (a) within seven days following the receipt of the Financing Notice by notifying the Issuer that it will provide such financing on the terms set out in the Financing Notice; or
- (b) within seven days following the receipt of the Q.T. Notice and the Q.T. Reports by notifying the Issuer that it will provide sponsorship on terms to be mutually agreed upon by the parties.

14.5 If the Agent fails to give the applicable notice within seven days, the Issuer will then be free to make other arrangements to obtain financing or sponsorship from another source on the same terms or on terms no less favourable to the Issuer, subject to obtaining the acceptance of the Regulatory Authorities.

14.6 The right of first refusal will not terminate if, on receipt of any Financing Notice or Q.T. Notice from the Issuer, the Agent fails to exercise the right.

15. ASSIGNMENT AND SELLING GROUP PARTICIPATION

15.1 The Agent will not assign this Agreement or any of its rights under this Agreement or, with respect to the Securities, enter into any agreement in the nature of an option or a sub-option unless and until, for each intended transaction, the Agent has obtained the consent of the Issuer and notice has been given to and accepted by the Regulatory Authorities.

15.2 The Agent may offer selling group participation in the normal course of the brokerage business to selling groups of other licensed dealers, brokers and investments dealers, who may or who may not be offered part of the commissions or warrants to be received by the Agent pursuant to this Agreement.

16. NOTICE

16.1 Any notice under this Agreement will be given in writing and must be delivered, sent by facsimile transmission or mailed by prepaid post and addressed to the party to which notice is to be given as follows unless otherwise designated by such party in writing:

(a) if to the Issuer:

Auricle Biomedical Corporation
208-5455 West Boulevard
Vancouver, British Columbia V6M 3WS

Attention: Punit Dhillon
Facsimile: (858) 777-5481

with a copy to:

Lawson Lundell LLP
1600-925 West Georgia Street
Vancouver, British Columbia V6C 3L2

Attention: Cheryl Hsu
Facsimile: (604) 694-2928

(b) if to the Agent:

Canaccord Capital Corporation
2200-609 Granville Street
Vancouver, British Columbia V7Y 1H2

Attention: Glenda Chin
Facsimile: (604) 643-7733

with a copy to:

Miller Thomson LLP
Robson Court, 1000-840 Howe Street
Vancouver, British Columbia V6Z 2M1

Attention: Kevin Sorochan
Facsimile: (604) 643-1200

16.2 If notice is sent by facsimile transmission or is delivered, it will be deemed to have been given at the time of transmission or delivery.

16.3 If notice is mailed, it will be deemed to have been received 48 hours following the date of mailing of the notice.

16.4 If there is an interruption in normal mail service due to strike, labour unrest or other cause at or prior to the time a notice is mailed the notice will be sent by facsimile transmission or will be delivered.

17. TIME

Time is of the essence of this Agreement and will be calculated in accordance with the provisions of the *Interpretation Act* (British Columbia).

18. SURVIVAL OF REPRESENTATIONS AND WARRANTIES

The representations, warranties, covenants and indemnities of the parties contained in this Agreement will survive the closing of the purchase and sale of the Securities.

19. LANGUAGE

Wherever a singular or masculine expression is used in this Agreement, that expression is deemed to include the plural, feminine or the body corporate where required by the context.

20. ENUREMENT

This Agreement enures to the benefit of and is binding on the parties to this Agreement and their successors and permitted assigns.

21. HEADINGS

The headings in this Agreement are for convenience of reference only and do not affect the interpretation of this Agreement.

22. ENTIRE AGREEMENT

This Agreement constitutes the entire agreement and supersedes any other previous agreement between the parties with respect to the Offering and there are no other terms, conditions, representations or warranties whether express, implied, oral or written by the Issuer or the Agent.

23. COUNTERPARTS

This Agreement may be executed in two or more counterparts, each of which will be deemed to be an original and all of which will constitute one agreement, effective as of the reference date given above.

24. LAW

This Agreement and its application and interpretation will be governed exclusively by the laws prevailing in British Columbia. The parties to this Agreement consent to the jurisdiction of the courts of British Columbia, which courts shall have exclusive jurisdiction over any dispute of any kind arising out of or in connection with this Agreement.

[This space has been left intentionally blank]

This document was executed and delivered as of the date given above.

**AURICLE BIOMEDICAL
CORPORATION**

Per: "Vincent Lum"
Chief Executive Officer

Per: "Punit Dhillon"
Chief Financial Officer

**CANACCORD CAPITAL
CORPORATION**

Per: "David J. Horton"
Authorized Signatory

Per: "David Rentz"
Authorized Signatory

I/We have the authority to bind the corporation

SCHEDULE A

Opinion of Issuer's Counsel

The opinion of the Issuer's counsel shall be in respect of the following matters:

1. as to the due incorporation and valid existence of the Issuer under the laws of its jurisdiction of incorporation and as to the adequacy of the power and capacity of the Issuer to carry out its obligations under this Agreement;
2. as to the authorized capital of the Issuer and that the Issuer's outstanding common shares have been duly and validly allotted and issued as fully paid and non-assessable common shares in the capital of the Issuer;
3. that the Issuer has all requisite power and capacity under the laws of its jurisdiction of incorporation, as the case may be, to carry on its business as presently conducted;
4. that all necessary action has been taken by the Issuer to authorize the execution and delivery of this Agreement and the performance by the Issuer of its obligations under this Agreement and the execution and filing of the Prospectus under the Applicable Legislation;
5. that all necessary action has been taken by the Issuer to duly authorize and validly issue the Securities on the terms and conditions of this Agreement;
6. that the attributes of the Shares and the Agent's Warrants are consistent in all material respects with the description thereof contained or referred to in the Prospectus;
7. upon the payment therefor, that the Shares sold pursuant to the Offering have been issued and are outstanding as fully paid shares of the Issuer;
8. that this Agreement and the certificates representing the Agent's Warrants have been duly executed and delivered by the Issuer and each constitutes a legal, valid and binding obligation of the Issuer, enforceable against the Issuer in accordance with their respective terms subject to customary exceptions;
9. that all necessary documents have been filed, all requisite proceedings have been taken and all other legal requirements have been fulfilled by the Issuer under the Applicable Legislation to qualify the Shares for distribution to the public in each Selling Province through registrants or dealers registered under the applicable legislation of such Selling Provinces who have complied with the relevant provisions of such legislation and the terms of their registrations, and for distribution of the Agent's Warrants to the Agent;
10. that no prospectus or other document is required under Applicable Legislation, and except as have been obtained or completed, no proceeding is required to be taken and no approval, consent or authorization of or filing with, the Commissions is required in order to permit the issuance by the Issuer of the Agent's Warrant Shares upon the due exercise of the Agent's Warrants, and in accordance with the terms of the certificate representing the Agent's Warrant;

11. that the Agent's Warrants have been duly created and validly authorized and the Agent's Warrant Shares have been allotted and reserved for issuance and will be duly and validly issued as fully paid and non-assessable upon exercise in accordance with the terms of the certificate representing the Agent's Warrants;
12. that the first trade in, or resale of, as applicable, the Agent's Warrant Shares is exempt from, or is not subject to, the prospectus requirements of the Applicable Legislation;
13. that neither the execution and delivery of, nor the performance of its obligations under this Agreement or the Agent's Warrant by the Issuer nor the creation, allotment and issuance of the Securities will conflict with or constitute a breach or default under the articles of the Issuer or any material agreement or other instrument to which the Issuer is a party or by which it is bound;
14. as to the Issuer's reporting issuer status in the Selling Provinces;
15. that subject only to the standard listing conditions, the Shares and the Agent's Warrant Shares have been conditionally listed on the Exchange;
16. that the form and terms of the certificates representing the common shares of the Issuer have been approved by the directors of the Issuer; and
17. that Pacific Corporate Trust Company has been duly appointed as transfer agent and registrar for the common shares of the Issuer.